SCHEMBL5675752

SCHEMBL5675752

Cc1ccc2c(c1)C(CC(=O)O)(c1ccccc1Cl)C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
MAPT P10636 2/20 0.46
ADAMTS5 Q9UNA0 1/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GSK3B P49841 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
IDO1 P14902 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADCY8 P40145 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5675711 0.87 MAPT (0.41) BRD4MAPTADAMTS5GAAALDH1A1
SCHEMBL16789224 0.78 BRD4 (0.47) BRD4MAPTADAMTS5GAAALDH1A1
SCHEMBL7467300 0.77 GAA (0.56) BRD4MAPTADAMTS5GAAALDH1A1
SCHEMBL5674285 0.76 KDM4E (0.49) MAPTALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL5678529 0.76 IDO1 (0.48) BRD4MAPTGAAIDO1SMN1; SMN2
SCHEMBL2492359 0.75 CBX7 (0.48) BRD4GAAKDM4ELMNAIDO1
SCHEMBL7470880 0.75 CYP1A2 (0.46) BRD4MAPTADAMTS5GAAALDH1A1
SCHEMBL5674357 0.74 BRD4 (0.39) BRD4ALDH1A1KDM4EIDO1SMN1; SMN2
SCHEMBL5678922 0.74 KMT2A (0.45) BRD4MAPTADAMTS5SMN1; SMN2POLB
SCHEMBL5674786 0.74 IDO1 (0.46) BRD4MAPTGAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119086-B2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2006-10-10 US disclosed
CN-1224623-C 1-phenylsulfonyl-1, 3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use SANOFI ANWANTE (FR) 2005-10-26 CN disclosed
CN-1533387-A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use ����ɳŵ��-����������˾ 2004-09-29 CN disclosed
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use AVPR2, AVPR1A, AVPR1B BRD4 2751/4885MAPT 3026/4885ADAMTS5 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.